CA Ⅱ
Carbonic Anhydrase II (CA II) is a cytosolic zinc metalloenzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate and a proton, a reaction central to acid-base homeostasis, carbon dioxide transport, and cellular pH regulation[1][2]. CA II is the best-characterized human carbonic anhydrase isoform and exhibits exceptionally high catalytic efficiency, making it a key regulator of bicarbonate-dependent physiological processes in erythrocytes, kidney, bone, eye, and other tissues[2][3]. Mechanistically, CA II supports bicarbonate transport and acidification pathways that are required for renal bicarbonate reabsorption and osteoclast-mediated bone resorption[1][4]. In disease settings, inherited CA II deficiency causes the autosomal recessive syndrome characterized by osteopetrosis, renal tubular acidosis, and cerebral calcification, providing direct genetic evidence for the essential role of this isoform in bone and renal physiology[4][5]. Compared with related carbonic anhydrase isoforms, CA II is distinguished by its broad tissue distribution, dominant catalytic activity, and well-established involvement in bicarbonate transport metabolons and vascular regulatory processes[3][6]. These characteristics have made CA II one of the most extensively studied experimental models for enzyme catalysis, structure-guided drug discovery, and inhibitor development[3][7]. Sulfonamide-based carbonic anhydrase inhibitors, including clinically used agents, bind the catalytic zinc center and have been widely employed to investigate CA II function and therapeutic modulation in disorders such as glaucoma and other bicarbonate-dependent pathologies[6][7].
References:
- [1]. Sly WS, et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A. 1983 May;80(9):2752-6. [Content Brief]
- [2]. Roy BC, et al. Two-prong inhibitors for human carbonic anhydrase II. J Am Chem Soc. 2004 Oct 20;126(41):13206-7. [Content Brief]
-
CA Ⅱ Related Products (119)
Related Products (119)
-
Recombinant Proteins (3)
-
Carbonic anhydrase-IN-34
0 ImagesCat. No.: HY-175315Carbonic anhydrase-IN-34 is a carbonic anhydrases (CAs) inhibitor (compound 9d) with IC50s of 1.01 μM against hCA-II, 0.21 μM against hCA-IX and 0.88 μM against hCA-XII. Carbonic anhydrase-IN-34 has potential applications in the research of several disorders, including epilepsy, glaucoma, obesity, and cancer.
-
CAII-IN-13
0 ImagesCat. No.: HY-181238CAII-IN-13 is a human carbonic anhydrase inhibitor, with a Ki of 65.9 nM against human carbonic anhydrase II and a Ki of 968.4 nM against human carbonic anhydrase I. CAII-IN-13 functionally inhibits the catalytic activities of human carbonic anhydrase II and human carbonic anhydrase I. CAII-IN-13 satisfies the Lipinski's rule of five and may possess physicochemical properties and pharmacokinetic profiles associated with in vivo bioavailability.
-
Phenylsulfamide
0 ImagesPhenylsulfamide (Compound 10) is a human carbonic anhydrase-II (hCA-II) inhibitor with a Kd of 45.50 μM and a Ki of 79.60 μM.
-
CAI/II-IN-12
0 ImagesCat. No.: HY-175972CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma.
-
Vescalagin
0 ImagesCat. No.: HY-N19401CAS No.: 36001-47-5Vescalagin is a hexahydroxyphenol. Vescalagin is isolable from Camu-camu (Myrciaria dubia) and immature wax apple fruits. Vescalagin exhibits inhibitory activity against a variety of enzymes, with a Ki value of 5.87 nM against AChE, 3.89 nM against BChE, 11.75 nM against hCA I, 16.23 nM against hCA II, and 16.08 nM against α-glucosidase. Vescalagin inhibits hCA I, hCA II and α-glucosidase in a non-competitive manner. Vescalagin downregulates JNK/p38 MAPK to protect pancreatic β-cells and improve insulin secretion in methylglyoxal-treated rats. Vescalagin reduces hyperglycemia and hypertriglyceridemia in rats fed a high-fructose diet. Vescalagin possesses anti-inflammatory and antioxidant properties.
-
CAI/II-IN-10
0 ImagesCat. No.: HY-172103CAS No.: 3116551-74-4CAI/II-IN-10 (Compound 5d) is a human carbonic anhydrase I and II (hCA I and hCA II) inhibitor with IC< The sub>50 values are 4.32 and 3.89 nM respectively.
-
Dorzolamide-d5
0 ImagesCat. No.: HY-B0109SCAS No.: 1227097-70-2Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
-
Dealanylascamycin
0 ImagesCat. No.: HY-101136CAS No.: 66522-52-9Synonyms: AT-265Dealanylascamycin (AT-265) (Compound 2) is a nucleoside antibiotic. AT 265 is a carbonic anhydrase (CA) inhibitor, with Ki values of 167, 65.2, 234, and 143 nM for hCA I, hCA II, hCA IV, and hCA IX respectively. Dealanylascamycin is the active form of Ascamycin (HY-121071). Dealanylascamycin exhibits broad-spectrum antibacterial activity and is effective against pathogenic bacteria such as Xanthomonas citri (MIC = 0.4 μg/mL). Dealanylascamycin has high cytotoxicity.
-
L-662583
0 ImagesCat. No.: HY-125375CAS No.: 119731-75-8L-662583 is a locally active carbonic anhydrase II inhibitor with an IC50 value of 0.7 nM.
-
Indisulam (Standard)
0 ImagesSynonyms: E 7070 (Standard)Indisulam (Standard) (E 7070 (Standard)) is the analytical standard of Indisulam (HY-13650). This product is intended for research and analytical applications. Indisulam (E 7070) is a carbonic anhydrase inhibitor and RBM39 molecular glue degrader, with Ki values of 31, 15, and 24 nM against human carbonic anhydrase I, II, and IX, respectively, and a Ki value of 65 nM against bovine carbonic anhydrase IV. Indisulam promotes the recruitment of RBM39 to the CUL4-DCAF15 E3 ubiquitin ligase complex, triggering polyubiquitination and proteasomal degradation of RBM39. Indisulam induces aberrant pre-mRNA splicing, G1 cell cycle arrest, and cell death in cancer cells. As an anticancer agent, Indisulam drives tumor regression and growth inhibition in xenograft models. Indisulam can be used in research related to solid tumors, hematologic and lymphoid malignancies, colorectal cancer, and non-small cell lung cancer.
-
Carbonic anhydrase inhibitor 25
0 ImagesCat. No.: HY-163753Carbonic anhydrase inhibitor 25 (compound 6a) is a potent carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 25 shows inhibition for hCA I and hCA II receptor.
-
CAI/II-IN-7
0 ImagesCAI/II-IN-7 (compound 1F) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively.
-
Carbonic anhydrase inhibitor 19
0 ImagesCat. No.: HY-162226CAS No.: 3033374-40-9Carbonic anhydrase inhibitor 19 (compound 26a) inhibits the Glaucoma related isoforms hCA II and hCA XII with Kis of 9.4 nM and 6.7 nM, respectively. Carbonic anhydrase inhibitor 19 reveals an intraocular pressure (IOP) lowering effect.
-
CAII/lX-IN-2
0 ImagesCAII/lX-IN-2 is a carbonic anhydrase inhibitor with an IC50 of 2.2 nM against hCA IX and 19.8 nM against hCA XII. CAII/lX-IN-2 inhibits the catalytic activities of cytosolic hCA I, hCA II, and transmembrane tumor-associated hCA IX and hCA XII in a concentration-dependent manner. CAII/lX-IN-2 can be used in research related to metastatic solid tumors.
